A
77.36
0.66 (0.86%)
| Previous Close | 76.70 |
| Open | 76.80 |
| Volume | 279,298 |
| Avg. Volume (3M) | 462,324 |
| Market Cap | 1,737,363,840 |
| Price / Earnings (TTM) | 48.35 |
| Price / Earnings (Forward) | 8.70 |
| Price / Sales | 1.84 |
| Price / Book | 3.29 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2026 |
| Profit Margin | -3.12% |
| Operating Margin (TTM) | 7.61% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 43.40% |
| Quarterly Earnings Growth (YOY) | -13.90% |
| Total Debt/Equity (MRQ) | 142.03% |
| Current Ratio (MRQ) | 2.66 |
| Operating Cash Flow (TTM) | 80.74 M |
| Levered Free Cash Flow (TTM) | 39.80 M |
| Return on Assets (TTM) | 0.82% |
| Return on Equity (TTM) | -4.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | ANI Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 5.0 |
| Insider Activity | -2.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.40 |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 11.08% |
| % Held by Institutions | 100.39% |
| 52 Weeks Range | ||
| Median | 124.00 (60.29%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 16 Jan 2026 | 124.00 (60.29%) | Buy | 84.83 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CAREY STEPHEN P. | 77.15 | 74.75 | 12,148 | 957,564 |
| COOK MEREDITH | 77.15 | 73.90 | 12,340 | 957,085 |
| DAVIS KRISTA | 77.15 | 73.90 | 9,255 | 719,077 |
| GASSERT CHAD | 77.15 | 73.90 | 8,895 | 693,468 |
| GUTWERG ORI | 77.15 | 75.00 | 8,688 | 679,660 |
| LALWANI NIKHIL | 77.15 | 73.90 | 63,375 | 4,929,087 |
| MUTZ CHRISTOPHER | 77.15 | 74.56 | 18,668 | 1,448,259 |
| ROWLAND THOMAS ANDREW | 77.15 | 73.90 | 5,393 | 418,111 |
| SHANMUGAM MUTHUSAMY | 77.15 | - | 11,116 | 857,599 |
| WALSH PATRICK D | - | 76.10 | -6,000 | -456,600 |
| Aggregate Net Quantity | 143,878 | |||
| Aggregate Net Value ($) | 11,203,310 | |||
| Aggregate Avg. Buy ($) | 77.15 | |||
| Aggregate Avg. Sell ($) | 74.52 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CAREY STEPHEN P. | Officer | 05 Mar 2026 | Sell (-) | 7,312 | 75.60 | 552,787 |
| CAREY STEPHEN P. | Officer | 05 Mar 2026 | Option execute | 3,312 | - | - |
| WALSH PATRICK D | Director | 03 Mar 2026 | Sell (-) | 6,000 | 76.10 | 456,600 |
| GUTWERG ORI | Officer | 03 Mar 2026 | Sell (-) | 2,060 | 76.10 | 156,766 |
| MUTZ CHRISTOPHER | Officer | 02 Mar 2026 | Automatic sell (-) | 417 | 75.22 | 31,367 |
| CAREY STEPHEN P. | Officer | 28 Feb 2026 | Disposed (-) | 2,773 | 73.90 | 204,925 |
| COOK MEREDITH | Officer | 28 Feb 2026 | Disposed (-) | 1,555 | 73.90 | 114,915 |
| DAVIS KRISTA | Officer | 28 Feb 2026 | Disposed (-) | 1,555 | 73.90 | 114,915 |
| GASSERT CHAD | Officer | 28 Feb 2026 | Disposed (-) | 2,221 | 73.90 | 164,132 |
| GUTWERG ORI | Officer | 28 Feb 2026 | Disposed (-) | 2,221 | 73.90 | 164,132 |
| LALWANI NIKHIL | Officer | 28 Feb 2026 | Disposed (-) | 12,217 | 73.90 | 902,836 |
| MUTZ CHRISTOPHER | Officer | 28 Feb 2026 | Disposed (-) | 2,221 | 73.90 | 164,132 |
| ROWLAND THOMAS ANDREW | Officer | 28 Feb 2026 | Disposed (-) | 628 | 73.90 | 46,409 |
| CAREY STEPHEN P. | Officer | 26 Feb 2026 | Acquired (+) | 22,233 | 77.15 | 1,715,276 |
| COOK MEREDITH | Officer | 26 Feb 2026 | Acquired (+) | 13,895 | 77.15 | 1,071,999 |
| DAVIS KRISTA | Officer | 26 Feb 2026 | Acquired (+) | 10,810 | 77.15 | 833,992 |
| GASSERT CHAD | Officer | 26 Feb 2026 | Acquired (+) | 11,116 | 77.15 | 857,599 |
| GUTWERG ORI | Officer | 26 Feb 2026 | Acquired (+) | 12,969 | 77.15 | 1,000,558 |
| LALWANI NIKHIL | Officer | 26 Feb 2026 | Acquired (+) | 75,592 | 77.15 | 5,831,923 |
| MUTZ CHRISTOPHER | Officer | 26 Feb 2026 | Acquired (+) | 21,306 | 77.15 | 1,643,758 |
| ROWLAND THOMAS ANDREW | Officer | 26 Feb 2026 | Acquired (+) | 6,021 | 77.15 | 464,520 |
| SHANMUGAM MUTHUSAMY | Officer | 26 Feb 2026 | Acquired (+) | 11,116 | 77.15 | 857,599 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities |
| 06 Jan 2026 | Announcement | ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |